Scalper1 News
Biotech Bluebird Bio (BLUE) saw its stock fly to an all-time high Tuesday following a researcher’s report from the annual meeting of the American Society of Hematology that two patients with a killer blood disease have been able to forgo blood transfusions for at least five months after being treated with the company’s technique to replace the defective gene that causes the condition. Bluebird focuses on treating patients using gene therapy, a Scalper1 News
Scalper1 News